BLAINTRAVITREALINJECTABLEPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VABYSMO (faricimab) is a bispecific antibody (BSAB) developed by Roche and approved by the FDA on January 28, 2022, for intravitreal injection. It treats multiple retinal conditions including diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusion, diabetic retinopathy, choroidal neovascularization, polypoidal choroidal vasculopathy, and radiation retinopathy. As a bispecific antibody, faricimab simultaneously targets two pathways—angiopoietin-2 and vascular endothelial growth factor (VEGF)—offering a dual mechanism approach to address both vascular instability and neovascularization.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
Started May 2026
100 enrolled
Macular Degeneration, Age Related
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
Started Aug 2025
120 enrolled
Polypoidal Choroidal Vasculopathy
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Started Aug 2025
426 enrolled
Proliferative Diabetic Retinopathy (PDR)
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Started Mar 2025
274 enrolled
Neovascular Age-related Macular Degeneration (nAMD)
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
Started Feb 2025
850 enrolled
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Worked on VABYSMO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.